We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Show more
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., March 28, 2024 Enrollment in CARPO, Phase 2b trial of Auxora™ in acute...
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., March 13, 2024 Therapeutic...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., Feb. 28...
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury PR Newswire LA JOLLA, Calif., Feb. 13, 2024 Phase 2 trial...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire LA JOLLA, Calif., Feb. 7, 2024 LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ -- CalciMedica...
CalciMedica Announces Private Placement of up to Approximately $55 Million PR Newswire LA JOLLA, Calif., Jan. 22, 2024 $20.4 million in upfront financing with the potential to receive up to an...
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., Nov. 9, 2023 Continued expansion of Phase 1/2 CRSPA study of...
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition PR Newswire LA JOLLA, Calif., Nov. 2, 2023 Auxora™ showed a 53...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1913 | -4.41934067965 | 4.3287 | 4.58 | 4.01 | 3024 | 4.3224369 | CS |
| 4 | 0.0374 | 0.912195121951 | 4.1 | 4.59 | 3.87 | 15499 | 4.28076463 | CS |
| 12 | -3.0426 | -42.3760445682 | 7.18 | 8.38 | 3.3101 | 21491 | 4.66057219 | CS |
| 26 | 2.2674 | 121.251336898 | 1.87 | 8.38 | 1.75 | 18389 | 4.22750433 | CS |
| 52 | -0.5626 | -11.970212766 | 4.7 | 8.59 | 1.75 | 18407 | 3.88370789 | CS |
| 156 | -1.1326 | -21.4914611006 | 5.27 | 8.59 | 1.75 | 19298 | 4.02778344 | CS |
| 260 | -1.1326 | -21.4914611006 | 5.27 | 8.59 | 1.75 | 19298 | 4.02778344 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
